CJC-1295 vs Alpha-GPC
Side-by-side comparison of key properties, dosing, and research.
- Summary
- CJC-1295 is a synthetic GHRH analog that stimulates the pituitary gland to produce and release growth hormone. The DAC (Drug Affinity Complex) version has a markedly extended half-life. The No DAC version (Modified GRF 1-29) preserves natural pulsatile GH release and is preferred in most protocols.
- Alpha-GPC is the most bioavailable form of choline, readily crossing the blood-brain barrier to rapidly increase acetylcholine levels. It enhances cognitive performance, supports GH secretion, and is used as an essential complement to many nootropic peptides (especially those that increase acetylcholine demand like Noopept and Dihexa).
- Half-Life
- ~30 minutes (No DAC) / 6–8 days (with DAC)
- ~4–6 hours
- Admin Route
- SubQ
- Oral, SubQ
- Research
- —
- —
- Typical Dose
- 100 mcg
- 300–600 mg
- Frequency
- Once daily, before bed
- 1–2x daily
- Key Benefits
- Sustained increase in growth hormone levels
- Enhanced muscle growth and strength
- Improved fat metabolism and body composition
- Better recovery and tissue repair
- Increased bone density
- Enhanced immune function
- Improved skin quality and collagen production
- Synergistic GH release when combined with GHRPs like Ipamorelin
- Rapidly raises brain acetylcholine levels
- Enhances memory formation and recall
- Prevents headaches from nootropic peptides (choline donor)
- Stimulates growth hormone secretion (modest)
- Improves attention and processing speed
- Neuroprotective in Alzheimer's and cognitive decline
- Approved in Europe for Alzheimer's therapy
- Enhances power output in athletes (pre-workout)
- Side Effects
- Water retention / puffiness
- Carpal tunnel syndrome (with prolonged use)
- Injection site irritation
- Hunger increase (minor)
- +1 more
- Headache (paradoxically, from excess acetylcholine at very high doses)
- Nausea at doses > 1200 mg
- Dizziness
- Fatigue at high doses
- +1 more
- Stacks With
- —
- —